C$0.285 %
Last Trade - 05/02/20
| Market Cap | £225.3m |
| Enterprise Value | £73.2m |
| Revenue | £6.26m |
| Position in Universe | th / 2794 |
| Relative Strength (%) | ||
|---|---|---|
| -34.3% | ||
| Volume Change (%) | ||
|---|---|---|
| Price vs... (%) | ||
|---|---|---|
| 12m Forecast Rolling | Industry | Market |
|---|---|---|
|
n/a
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Valuation (ttm) | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 4.13 | 15.2 | 24.5 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2022
|
31st Dec 2023
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Zomedica Corp. is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. The Company is developing point-of-care diagnostic platform, which is based on miniaturized laser-based Raman spectroscopy technology and is designed to detect pathogens in companion animals. Its product portfolio includes diagnostics and therapeutic medical devices that emphasize patient health. It offers TRUFORMA is a diagnostic biosensor platform and the first five assays for the detection of thyroid disorders in dogs and cats and adrenal disorders in dogs. The TRUFORMA platform uses bulk acoustic wave (BAW) technology to provide a non-optical and fluorescence free detection system for use at the point-of-care. The TRUFORMA also offers complete control over the testing process and allow veterinarians to make clinical decisions. PulseVet platform provides treatment for musculoskeletal issues in horses and small animals.
| Last Annual | December 31st, 2021 |
| Last Interim | March 31st, 2022 |
| Incorporated | January 7, 2013 |
| Public Since | October 28, 2013 |
| No. of Shareholders: | n/a |
| No. of Employees: | 47 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | TSX Venture Exchange |
| Shares in Issue | 979,899,668 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 100 Phoenix Drive Suite 125, ANN ARBOR, 48108, United States |
| Web | http://www.zomedica.com/ |
| Phone | +1 734 3692555 |
| Contact | () |
| Auditors | Grant Thornton LLP |
As of 05/02/20, shares in Zomedica Pharmaceuticals are trading at C$0.285, giving the company a market capitalisation of £225.3m. This share price information is delayed by 15 minutes.
Shares in Zomedica Pharmaceuticals are currently trading at C$0.285 and the price has moved by -83.24% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zomedica Pharmaceuticals price has moved by -83.76% over the past year.
There are no analysts currently covering Zomedica Pharmaceuticals.
Zomedica Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:
Zomedica Pharmaceuticals does not currently pay a dividend.
Zomedica Pharmaceuticals does not currently pay a dividend.
Zomedica Pharmaceuticals does not currently pay a dividend.
To buy shares in Zomedica Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Zomedica Pharmaceuticals are currently trading at C$0.285, giving the company a market capitalisation of £225.3m.
Here are the trading details for Zomedica Pharmaceuticals:
We were not able to load our ranking data for Zomedica Pharmaceuticals
We were not able to load any forecast data for Zomedica Pharmaceuticals.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zomedica Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 3.75%. At the current price of C$0.285, shares in Zomedica Pharmaceuticals are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Zomedica Pharmaceuticals.
Zomedica Pharmaceuticals's management team is headed by:
Here are the top five shareholders of Zomedica Pharmaceuticals based on the size of their shareholding:
